CV E. Brouwer 12 february 2024

Personal Details
Naam: E. Brouwer, Elisabeth
Adres: Nolenslaan 27
Postcode: 9722 NL
Woonplaats: Groningen
Geboortedatum: 19-08-1962
Nationaliteit: Dutch
Telefoon: 050-3616161 (UMCG)
Mobile Phone: 06-25095814
E-mail: e.brouwer@umcg.nl
Social media LinkedIn
University page PURE https://research.rug.nl/en/persons/liesbeth-brouwer

Education MD PhD
WO Professor Translational Rheumatology, in particular the Vasculitides
University of Groningen, degree 2020
WO PhD University of Groningen, degree 1994
WO Medical Doctor University of Groningen , degree 1988 BIG register 99020318501

Specialization
 Rheumatologist University Medical Center Groningen, registered in 2003
 Internist University Medical Center Groningen , registered in 1999
 Immunology via de Stichting voor opleiding tot Medisch-Biologisch Wetenschappelijk Onderzoeker (SMBWO), degree 1994 GCP, Leadership and Education
 Good Clinical Practice, registration in 2009 and reregistration in 2019
 Leader of professionals (LAP), participation 2018
 Basis Kwalificatie Onderwijs (BKO), degree 2017

Research profile
2003 - present Professor translational rheumatology with a focus on vasculitis (Department Rheumatology and Clinical Immunology UMCG)
The vasculitis expertise center at the UMCG has expertise in all major forms of vasculitis including child hood and CNS vasculitis and is the
leading vasculitis center in the Netherlands. www.vasculitiscentrum.nl My research lines focus on translational studies into development of biomarkers including imaging for diagnosis and disease monitoring and treatment monitoring in large vessel vasculitis, giant cell arteritis(GCA) and its associated disease polymyalgia rheumatica (PMR). In my research I integrate basic, clinical and imaging data in order to improve outcome for patients with vasculitis.


12 February 2024

Network Scientific committees
2022 - present
2019 - present
2017 – present
2017 - present
2015 - present
2015 - present
Member of the board of ARCH Auto-immune Research Hub
ARCH is a non-profit foundation with as central aim to improve the care for patients for rare auto-immune diseases in the Netherlands Dutch Society of Rheumatology

President GCA-Guideline Committee
As president I am instrumental in the set up of state of the art care for giant cell arteritis patients GCA in the Netherlands Systemic Auto-immune diseases The Nederlands (SAN-NL)

Secretary Vasculitis Group
As secretary I coordinate vasculitis care and research in the Netherlands

Dutch Arthritis Foundation DAF
Member scientific advisory board.

Universitary Medical Center Groningen
Member Biobank Committee
Organization biobanks at the UMCG .

Universitary Medical Center Groningen
Chair Weekly Research Meeting

Grants International Collaboration Publications Societal Relevance Outreach
 Grants
 Collaboration
Listed are the most important grants
 Immune-Image EU IMI project specific imaging of immune cell
dynamics through novel tracer strategies
 PROMINENT Immune signatures in chronic inflammatory diseases:
focus on Interleukin-6.
 Dutch Arthritis Association Aged CD16+ monocytes promote T helper
17-mediated pathology and vascular damage in giant cell arteritis (in
2015)
 RELENT RELapses prevENTion in chronic autoimmune disease
common mechanisms and co-morbidities WP3 the ageing immune
system and its relation to the development of autoimmunity and co
morbidities.
For Complete overview see: Liesbeth Brouwer — the University of
Groningen research portal (rug.nl)
National and International:
CV E. Brouwer 12 february 2024
 Chair of the development and implementation of the GCA/PMR
guidelines both EULAR European League against rheumatism and BSR
British Society of Rheumatology
 EUVAS European vasculitis and Vasculitis Foundation US
 National PI and initiator of the treatment with leflunomide in
patients with Polymyalgia Rheumatica (PMRLEFRCT) ClinicalTrials.gov
Identifier: NCT03576794
 Chair of the DLVVSG (Dutch Large Vessel Vasculitis Study Group)
 Publications
 Outreach Author of more than 150 articles, examples in high ranked papers:
 2018 Update of the EULAR recommendations for the management of large vessel vasculitis ARD (accepted 2019) Number 1 original research journal in Rheumatology
 What Is the current evidence for disease subsets in giant cell arteritis? AR (2018) Number 2 original research journal in Rheumatology
 FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG) ARD (2018) Number 1 original research journal in Rheumatology
 Trial of tocilizumab in giant-cell arteritis NEJM (2017) nr 1 original research journal in general medicine
Listed are the most relevant societal activities
 2023 Dutch Guideline GCA
 2022 E learning GCA
 2019 March 12 Presentation “Medical Public Presentation University
Medical Hospital Groningen on Polymyalgia Rheumatica
 2018 Sept Live PMR questions and answer session for the Dutch Arthritis Foundation (Reuma Nederland) https://www.facebook.com/ReumaNederland/
 2018 Nov 10 Lecture GCA state of the art Dutch vasculitis patient organization (Vasculitis Stichting) annual meeting Ede, the Netherlands
 2018 Guideline Tocilizumab Dutch society of rheumatology
 2018 Sept Focus Vasculair publication in Dutch for colleagues in the
Netherlands Title; Reuscelarteriitis; system-vasculitis of the large vessels